Introduction to Drug Interactions - PowerPoint PPT Presentation

1 / 17
About This Presentation
Title:

Introduction to Drug Interactions

Description:

Introduction to Drug Interactions Al Patterson, PharmD Drug Drug Interaction phenomena that occurs when the effects (pharmacodynamics) or pharmacokinetics ... – PowerPoint PPT presentation

Number of Views:137
Avg rating:3.0/5.0
Slides: 18
Provided by: ssTextcub
Category:

less

Transcript and Presenter's Notes

Title: Introduction to Drug Interactions


1
Introduction to Drug Interactions
  • Al Patterson, PharmD

2
Drug Drug Interaction
  • phenomena that occurs when the effects
    (pharmacodynamics) or pharmacokinetics of a drug
    are altered by prior administration or
    co-administration of a second drug
  • Hartshorn, EA, Tatro, DS Drug Interactions,
    2003, Facts and Comparisons, St. Louis, MO

3
Pharmacodynamic Drug Interaction
  • Extension of underlying pharmacology / toxicology
  • Potentiation
  • CNS sedation antihistamines / EtOH
  • MAOIs and SSRIs, Phenylephrine, etc
  • Digoxin toxicity with diuretic induced potassium
    wasting
  • QTc prolongation w/ Amiodarone and clarithromycin
  • Antagonism
  • Beta blockers used with terbutaline

4
Pharmacokinetic Drug Interactions
  • Absorption
  • Distribution
  • Metabolism
  • Elimination

5
Absorption
  • Inhibition of first pass metabolism
  • CYP 3A4 by erythromycin or grapefruit juice
  • Inc. concentration of atrovostatin myopathy
  • P-Glycoprotein inhibition by clarithromycin
  • Inc concentration of may drugs
  • Binding in gut delayed absorption
  • Antacids oral contraceptives

6
P-GlycoproteinActive Transport Efflux Pump
  • Biologic protective mechanism against hydrophobic
    substances (drugs) linked to CYP
  • Pumps drugs out of cells
  • Intestinal transport
  • Into the gut / prevents absorption
  • Into the bile
  • Renal transport
  • Into the tubule
  • Blood Brain Barrier
  • Out of the brain
  • Principle cause of multi-drug resistance in
    chemotherapy
  • Inhibited by many of the same drugs inhibiting
    3A4/5
  • Cyclosporine, ketoconazole, quinidine

7
P-Glycoprotein
http//www.hanstenandhorn.com/hh-article10-04.pdf
8
Distribution
  • Protein binding alterations
  • Displacement from albumin binding sites by acidic
    drugs
  • valproic acid displaces phenytoin increases
    free fraction of phenytoin increasing
    possibility of toxicity (total phenytoin
    concentration may appear normal only free
    fraction has pharmacodynamic effect)
  • Aspirin displaces warfarin increasing warfarin
    effect by both increasing free fraction and
    anti-platelet effect of aspirin

9
Protein Binding cont
  • Displacement from other binding site
  • Quinidine displaces digoxin from skeletal muscles
    sites by interfering with PGP increasing serum
    concentration of digoxin increases risk of
    toxicity (as well as quinidine interfering with
    renal clearance of digoxin)
  • http//www.hanstenandhorn.com/hh-article10-04.pdf

10
Metabolism
  • Most drugs must be lipid soluble to cross cell
    membranes and reach their site of action
  • The net effect of drug metabolism is to increase
    water solubility and facilitate renal excretion
  • Phase I metabolism primarily involves oxidative
    metabolism via the Cytochrome P450 (CYP) family
    of enzymes
  • Phase II metabolism conjugates the previously
    oxidized molecule with a water soluble weak acid
    (glucouronic acid, tauric acid, etc) enhancing
    overall water solubility

11
P450 Phase I Oxidation
http//www.qtdrugs.org/medical-pros/education/CERT
20Educational20Module201.ppt
12
Cytochrome P450 Nomenclature,e.g. for CYP2D6
  • CYP cytochrome P450
  • 2 genetic family
  • D genetic sub-family
  • 6 specific gene
  • NOTE that this nomenclature is genetically based
    it has NO functional implication
  • Isoforms variations of the enzyme

http//www.qtdrugs.org/medical-pros/education/CERT
20Educational20Module201.ppt
13
Cytochrome P450 Isoforms
Relative Importance ofP450s in Drug Metabolism
Relative Quantities of P450s in Liver
CYP1A2
CYP2E1
CYP1A2
CYP2C
?
CYP2C
CYP2D6
CYP3A4/5
CYP2E1
CYP3A
CYP2D6
CYP3A4/5
Shimada T et al. J Pharmacol Exp Ther
1994270(1)414.
14
CYP Inducers
  • Increase the activity of the enzyme systems
    therefore, increases the elimination of drugs
    that are substrates for that CYP isoform
  • Rifampin is potent inducer of CYP 3A4 and
    therefore would be predicted to increase the
    elimination of cyclosporine (ie. lower the
    cyclosporine serum concentration and increase
    risk of graft rejection)

15
CYP Inhibitors
  • Decreases the activity of the CYP isoform leading
    to reduced clearance of drugs that are
    metabolized by that CYP isoform
  • Erythromycin is a potent inhibitor of CYP 3A4 and
    has been shown dramatically reduce the metabolism
    of terfenadine (Seldane) which resulted in
    several deaths due to Torsades De Pointes (QTc
    prolongation) prompting the FDA to recall
    terfenadine in 2002

16
Renal Elimination
  • Primarily involves interference with active
    transport of organic acids and bases across the
    renal tubule
  • Probably involves P glycoprotien
  • Probenecid and penicillins (can be used
    therapeutically delays PCN clearance
  • Methotrexate and NSAIDs delays MTX clearance
    increase toxicity
  • Quinidine and Digoxin delays digoxin clearnace
    increase toxicity

17
Drug Interaction Resources
  • Drug Interaction Facts Facts and Comparisons
    quickly outdated
  • Online Multum Database updated daily
  • http//www.drugs.com/drug_interactions.html
  • Drugs effecting QTc
  • University of Arizona Health Sciences
  • http//www.arizonacert.org
  • Updated P450 data
  • http//medicine.iupui.edu/flockhart/table.htm
Write a Comment
User Comments (0)
About PowerShow.com